MEDANNEX LTD
Medannex's goal is to create a first-in-class antibody therapy to improve the lives of people impacted by cancers and autoimmune diseases.
MEDANNEX LTD
Industry:
Biotechnology Clinical Trials
Founded:
2009-01-01
Address:
Edinburgh, Edinburgh, City Of, United Kingdom
Country:
United Kingdom
Website Url:
http://www.medannex.org
Total Employee:
11+
Status:
Active
Contact:
+44(0)1313574251
Total Funding:
11 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Global Site Tag Mobile Non Scaleable Content Euro
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Parnell Living Science
Parnell is a fully integrated pharmaceutical company dedicated to finding animal health solutions that matter.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
VBI Vaccines
VBI Vaccinea is a biopharmaceutical company developing novel technologies that seek to expand vaccine.
Current Employees Featured
Founder
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series B - Medannex Ltd
Scottish Investment Bank
Scottish Investment Bank investment in Series B - Medannex Ltd
Official Site Inspections
http://www.medannex.org
- Host name: 39.129.153.160.host.secureserver.net
- IP address: 160.153.129.39
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Medannex Ltd"
Home page - Medannex
We are pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases. Annexin-A1 drives cancer cell growth …See details»
About - Medannex
Medannex recently initiated the First-in-Human clinical study of MDX-124, the only therapeutic monoclonal antibody to target annexin-A1, a protein which plays a key role in the development …See details»
Innovation - Medannex
Medannex has developed monoclonal antibodies to target annexin-A1, a protein that plays a key role in the immune system. MDX-124 - the first therapy to target annexin-A1 – has shown …See details»
Medannex - Crunchbase Company Profile & Funding
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. View contacts for Medannex to access new …See details»
Medannex Ltd - LinkedIn
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to …See details»
Medannex Announces First Patient Treated in Phase 1b Clinical …
Aug 21, 2023 · Medannex is pioneering the targeting of annexin-A1 to treat cancers and autoimmune conditions, and MDX-124 is the first medicine of its kind to enter clinical trials. …See details»
Medannex receives Orphan Designation from the European …
Mar 1, 2023 · Medannex Ltd (Edinburgh) announced today that MDX-124, a monoclonal antibody against annexin-A1, has received Orphan Medicinal Product positive opinion from the …See details»
FDA Grants US Orphan Designation to Medannex First-in-Class …
Sep 20, 2023 · About Medannex Ltd: Medannex is a clinical-stage Scottish biopharmaceutical company headquartered in Edinburgh. The company is developing novel treatments for …See details»
FDA Grants US Orphan Drug Designation to Medannex’s First-in …
Sep 20, 2023 · Medannex announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA). MDX-124, a first-in …See details»
Medannex Nature publication demonstrates anti-cancer effects of …
Nature publication demonstrates anti-cancer effects of MDX-124 in multiple tumour types. A new approach to cancer treatment. highlighting the anti-cancer effects of Medannex’s first-in-class …See details»
Medannex unveils First-in-Human study of novel cancer therapy at …
Jun 1, 2024 · Medannex Ltd (Edinburgh) today revealed details of the ATTAINMENT study at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 1b oncology study …See details»
Medannex’s First-in-class Therapy receives EMA Orphan …
Mar 2, 2023 · Medannex Ltd (Edinburgh) announced today that MDX-124, a monoclonal antibody against annexin-A1, has received Orphan Medicinal Product positive opinion from the …See details»
Medannex’s new therapy shows powerful synergy with common …
Aug 5, 2006 · Medannex’s new therapy shows powerful synergy with common cancer treatments. Medannex Ltd (Edinburgh) announced on 10th December 2021 the latest data on their new …See details»
Medannex unveils the multiple anti-cancer effects of MDX-124 at …
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti …See details»
Medannex Announces First Patient Treated in Phase 1b Clinical …
Aug 21, 2023 · Medannex is pioneering the targeting of annexin-A1 to treat cancers and autoimmune conditions, and MDX-124 is the first medicine of its kind to enter clinical trials. …See details»
£11m boost for leading Scottish antibody development company
Edinburgh-based biotechnology company MedAnnex Ltd has received a further £1m investment from The Scottish Investment Bank (SIB), the investment arm of Scotland’s national economic …See details»
News - Medannex
25.07.24 Medannex awarded ‘Transforming Cancer Therapeutics’ grant to accelerate new treatment for bone cancer in children. 01.06.24 Medannex unveils First-in-Human study of …See details»
Medannex’s monoclonal antibody MDX-124 highly active in …
Medannex Ltd (Edinburgh) today announced new data for their first-in-class targeted agent, MDX-124, showing significant anti-tumour activity in preclinical pancreatic cancer models. The …See details»
Medannex team grows to 12 employees, as preparations for First …
Jan 5, 2021 · Despite the challenges posed by the COVID-19 pandemic, Medannex completed its planned expansion to 12 employees over the course of 2020. With new in-house expertise in …See details»
Medannex: monoclonal antibody MDX 124 highly active in …
Jan 21, 2022 · Medannex has just presented new data at ASCO GI showing that our first-in-class annexin-A1 monoclonal antibody (MDX-124) has significant anti-tumour activity in pancreatic …See details»